HCPCS Code J7321: Hyaluronan or Derivative, Hyalgan, Supartz or Visco-3, for Intra-Articular Injection, Per Dose

Learn about the HCPCS code J7321 for "hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose."

Use Code

## **What is the HCPCS code J7321 for?** The HCPCS code J7321 is meant to designate the provision of an intra-articular hyaluronic acid or derivative injection (this could be a Hyalgan, Supartz, or Visco-3 branded). This is billed per dose. This specific injection's purpose is to provide lubrication and cushioning to a joint. In the context of this injection, it's primarily used on the knee joint, and therefore, it's commonly referred to as a knee injection. By providing lubrication to the joint, patients can enjoy improved mobility and joint function. By providing cushioning to the joint, patients can enjoy knee pain relief and improved comfort. It is mostly used on patients with knee osteoarthritis (e.g., unilateral secondary osteoarthritis, bilateral secondary osteoarthritis). It's one of the treatments provided before deciding to resort to knee replacement surgery. HCPCS code J7321 represents Hyalgan® (sodium hyaluronate) injection, used for intra-articular (IA) administration to treat pain associated with osteoarthritis (OA) of the knee in patients who have not responded adequately to conservative treatments such as NSAIDs, physical therapy, or simple analgesics.

## **Documentation requirements for J7321** As with any HCPCS code, you'll need to make sure that you have sufficient documentation that meets your insurer's coding guidelines and requirements for injection dose codes (e.g., Medicare benefit policy manual, Medicaid policies, local coverage determinations, etc.). Here are examples of what you need: - The full name of the patient - The full name and credentials of the professionals who handled/are handling the patient - The name and address of the facility where it was administered - The drug name, strength, and total dose administered, including the National Drug Code, date, lot number, and manufacturer of the injection - Route of administration (intra-articular) - Target joint (e.g., left knee, right knee) - Relevant information and indications from the patient's medical history to justify medical necessity - Treatment plan of the patient (e.g., course of injections, number of injections administered) - Provider order - Progress notes - Results of assessments used to examine the patient (e.g., Western Ontario and McMaster Universities Osteoarthritis Index) Documentation of failure of conservative therapy

## **Billing requirements for J7321** Besides the documentation requirements above, please make sure you take note of or have the following: - 1 unit equals 1 dose of the drug supplied - Report the actual number of units/doses administered - The relevant ICD code based on the patient's condition - Since this is injected intra-articularly, please use either one of these CPT codes: 20610 or 20611 - Coverage may be restricted to one knee per course unless bilateral treatment is medically justified Please familiarize yourself with the necessary coding guidelines and requirements based on your insurer, related policy articles, and local coverage determinations. Also, verify the current year's dosage and brand-to-code assignment against the payer's (e.g., DME MAC or specific payer) published fee schedules and articles, as these assignments can occasionally shift or be defined by separate codes.

## **Other similar codes** - **J7324** - Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose - **J7327** - Hyaluronan or derivative, monovisc, for intra-articular injection, per dose - **J7323** - Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose - **J7326** - Hyaluronan or derivative, gel-one, for intra-articular injection, per dose - **J7322** - Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg

Frequently asked questions

It can take up to 30 minutes to administer this injection.

It can take up to a week before the patient feels the improved lubrication and cushioning this injection provides.

Yes. The potential severe complications (albeit rare) include allergic reactions to the drug, bleeding inside the knee joint, and inflammation flare-ups.